AI Verification in Pharmaceutical Drug Discovery

AI accelerates research pipelines, but verification is the real bottleneck in pharmaceutical drug discovery. David Finkelshteyn, CEO of Pivotal AI, explores how pharmaceutical leaders approach validation, regulatory requirements, and responsible AI adoption when the stakes involve patient safety and scientific integrity.

The conversation examines why AI verification in pharma cannot follow the same playbook as other industries. Drug discovery demands a level of rigor where false positives carry regulatory, financial, and human consequences that compound across the development pipeline. Speed without verification creates risk that compounds rather than resolves.

Topics covered: AI verification and validation in pharmaceutical research, regulatory requirements for AI in drug discovery, responsible AI adoption in life sciences, the tension between speed and scientific rigor, and how pharma leaders evaluate AI tools for clinical and preclinical applications.